N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 182-190

  Mosnier, Jean François ^a,b,c   Kandel, Christine ^a,b   Cazals Hatem, Dominique ^d   Bou Hanna, Chantal ^a   Gournay, Jérome ^b   Jarry, Anne ^a   Laboisse, Christian L ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Tumorothèque de l'Ircna   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

Cholangiocarcinoma; E cadherin; N cadherin; Tissue microarrays

Indexed keywords

ANTIBODY; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; HEPATOCYTE PARAFFIN 1 PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT INJURY; BILE DUCT TUMOR; BILIARY CIRRHOSIS; CAUCASIAN; CELL MEMBRANE; CLINICAL ARTICLE; COLON ADENOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FROZEN SECTION; GALLBLADDER CARCINOMA; HAMARTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; LIVER; LIVER CARCINOMA; LIVER CELL; LIVER CELL CARCINOMA; MALE; NODULAR HYPERPLASIA; PANCREAS ADENOCARCINOMA; PERIHILAR CHOLANGIOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CADHERINS; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRANCE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KERATIN-7; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 59149105595     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.123     Document Type: Article

References (36)

1. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007;20:701-709.
2. Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977;39:232-246.
3. Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006;98:873-875.
4. Rullier A, LeBail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 2000;24:870-876.
5. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-1181.
6. Takeichi M. Cadherins: cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
7. Yamaoka K, Nouchi T, Tazawa J, et al. Expression of gap junction protein connexin 32 and E-cadherin in human hepatocellular carcinoma. J Hepatol 1995;22:536-539.
8. Kozyraki R, Scoazec JY, Flejou JF, et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996;110:1137-1149.
9. Ihara A, Koizumi H, Hashizume R, et al. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996;2:1441-1447.
10. Endo K, Ueda T, Ueyama J, et al. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31:558-565.
11. Matsumura T, Makino R, Mitamura K. Frequent downregulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001;7:594-599.
12. Wei Y, Van Nhieu JT, Prigent S, et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002;36:692-701.
13. Ashida K, Terada T, Kitamura Y, et al. Expression of E-cadherin, α-catenin, β-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinomas: an immunohistochemical study. Hepatology 1998;27:974-982.
14. ANAES. Recommandations pour la cryoconservation de cellules et tissus tumoraux dans le but de réaliser des analyses moléculaires. Ann Pathol 2001;21:184-201.
15. Liver Cancer Study Group. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd edn. Kanehara Publications: Tokyo, 1994.
16. Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl2 and p53 oncoprotein expression during colorectal tumorogenesis. Cancer Res 1995;55:237-241.
17. Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinomas: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005;207:156-163.
18. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finest branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004;39:1739-1745.
19. Roskams TA, van den Oord JJ, De Vos R, et al. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 1990;137:1019-1025.
20. Zhou H, Rogler LE, Teperman L, et al. Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver. Hepatology 2007;45:716-724.
21. Volk T, Geiger B. A 135 kDa membrane protein of intercellular adherens junctions. EMBO J 1984;3:2249-2260.
22. Biddlestone L, Fleming S. Morphological evidence that ACAM is a major intercellular adhesion molecule in human kidney. J Pathol 1991;164:9-15.
23. Uemura K, Kihara T, Kuzuya A, et al. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett 2006;402:278-283.
24. Reiss K, Maretzky T, Ludwig A, et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and β-catenin nuclear signalling. EMBO J 2005;24:742-752.
25. Desmet V. Embryology of the liver and intrahepatic biliary tract, and an overview of malformations of the bile duct. In: MacIntyre N, Benhamou JP, Bircher J, Rizzeto M, Rodes J (eds). Oxford Textbook of Clinical Hepatology, Vol. 1 Oxford University Press: Oxford, 1991, pp 497-501.
26. Scoazec JY, Bringuier AF, Medina JF, et al. The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications. J Hepatol 1997;26:543-553.
27. Haruna Y, Saito K, Spaulding S, et al. Identification of bipotential progenitor cells in human liver development. Hepatology 1996;23:476-481.
28. Shibahara H, Tamada S, Higashi M, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma - mass forming type. Hepatology 2004;39:220-229.
29. Fucich LF, Cheles MK, Thung SN, et al. Primary vs metastatic hepatic carcinoma. An immunohistochemical study of 34 cases. Arch Pathol Lab Med 1994;118:927-930.
30. Nakajima S, Doi R, Toyoda E, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004;10:4125-4133.
31. Yanagimoto K, Sato Y, Shimoyama Y, et al. Co-expression of N-cadherin and alpha-fetoprotein in stomach cancer. Pathol Int 2001;51:612-618.
32. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151.
33. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993;143:1050-1054.
34. Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008;88:78-88.
35. Leong ASY, Sormunen RT, Tsui WMS, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998;33:318-324.
36. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002;26:978-988.